Omrani Shaghayegh, Taheri Mohammad, Omrani Mir Davood, Arsang-Jang Shahram, Ghafouri-Fard Soudeh
Department of Neurology, Hamadan University of Medical Sciences, Hamadan, Iran.
Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clin Transl Med. 2019 Jan 16;8(1):3. doi: 10.1186/s40169-019-0220-2.
Long chain omega-3 fatty acids (omega-3 FAs) supplements have been shown to exert beneficial effects in patients with epilepsy through elevation of seizure thresholds and dampening of inflammatory responses. In this triple blind randomized, placebo-controlled parallel group trial of omega-3 FA supplementation, 180 mg eicosapentaenoic acid (EPA) and 120 mg docosahexaenoic acid (DHA) as well as placebo capsules were administered twice a day in 50 patients with refractory seizure during a 16-week period respectively. Seizure frequency and duration were reduced after completion of the treatment in the supplement group. The supplementation resulted in a significant decrease in TNF-α and IL-6 concentrations. Further studies are needed to compare different omega-3 FA compositions and determine the most effective dose and treatment duration as well as the long term benefits of this supplementation.
长链ω-3脂肪酸（ω-3 FAs）补充剂已被证明可通过提高癫痫发作阈值和减轻炎症反应，对癫痫患者产生有益影响。在这项ω-3 FA补充剂的三盲随机、安慰剂对照平行组试验中，180毫克二十碳五烯酸（EPA）和120毫克二十二碳六烯酸（DHA）以及安慰剂胶囊，分别在16周内每天两次给予50例难治性癫痫患者。补充剂组治疗结束后癫痫发作频率和持续时间降低。补充剂导致肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）浓度显著降低。需要进一步研究来比较不同的ω-3 FA成分，并确定最有效的剂量和治疗持续时间以及这种补充剂的长期益处。
